The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Pulmonary hypertension (PH) is a serious complication of COPD which is associated with
shorter survival, more frequent exacerbation, and increased use of health resources. There is
no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators
wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on
exercise capacity of severe COPD patients.